The Anthem Biosciences IPO has created a wave in India’s primary market due to its exceptional investor interest, skyrocketing grey market premium (GMP), and strong fundamentals. With allotment finalized on July 17, 2025, all eyes are now on listing gains and refund timelines. In this article, we break down every critical detail—from company background and IPO structure to allotment status, grey market trends, and what investors can expect next.
Overview of Anthem Biosciences
Anthem Biosciences Pvt Ltd is a Bengaluru-based contract research and manufacturing services (CRAMS) company focused on biotechnology and pharmaceuticals. With a diverse range of services in drug discovery, development, and manufacturing, Anthem serves both domestic and international pharmaceutical clients.
Key Highlights:
- Established: 2007
- Headquarters: Bengaluru, Karnataka
- Sector: Pharma & Biotech (CRAMS)
- Core Services: CDMO (Contract Development & Manufacturing Organization), biopharmaceuticals, R&D services
- Customers: Top global pharma and biotech firms
Their integrated facilities and quality-driven approach have made Anthem one of the top players in India’s biosciences ecosystem.
Anthem Biosciences IPO Summary
| IPO Feature | Details |
| IPO Open Date | July 12, 2025 |
| IPO Close Date | July 15, 2025 |
| Allotment Date | July 17, 2025 |
| Refund Initiation | July 18, 2025 |
| Listing Date (Expected) | July 21, 2025 |
| Issue Size | ₹1,500 Crores |
| Price Band | ₹560 – ₹570 per share |
| Lot Size | 26 shares |
| Minimum Investment (Retail) | ₹14,820 (at ₹570) |
| Listing Exchanges | NSE & BSE |
| Registrar | KFin Technologies Ltd. |
IPO Subscription Status: Massive Demand!
Anthem Biosciences saw one of the highest subscription numbers in 2025, indicating the faith investors have in the company’s long-term growth.
Final Subscription Figures:
| Category | Subscription (Times) |
| Qualified Institutional Buyers (QIBs) | 182× |
| Non-Institutional Investors (NIIs) | 42.3× |
| Retail Individual Investors (RIIs) | 5.6× |
| Employees & Others | 3.8× |
| Total Subscription | 64× overall |
The QIB segment was the most bullish, suggesting strong institutional confidence in Anthem’s business model.
Grey Market Premium (GMP): Pre-Listing Buzz
The GMP for Anthem Biosciences IPO has been on a sharp upward trend since the IPO opened.
- Day 1 GMP: ₹88
- Day 2 GMP: ₹105
- Day 3 GMP: ₹122
- On Allotment Day (July 17): ₹138–154
With the upper price band at ₹570, investors are anticipating a listing price between ₹708–₹724. That’s a 24–27% premium, driven by solid demand and market sentiment.
How to Check Anthem Biosciences IPO Allotment Status
The allotment status has been finalized on July 17, and here’s how you can check it:
Option 1: KFin Technologies (Registrar)
- Visit: https://kfintech.com/
- Click on “IPO Allotment Status”
- Select “Anthem Biosciences IPO”
- Enter PAN / Application No. / DP ID-Client ID
- Click on “Submit”
Option 2: BSE India
- Go to https://www.bseindia.com/investors/appli_check.aspx
- Select “Equity” and then choose “Anthem Biosciences”
- Enter PAN and application number
- Submit to view your allotment status
Refunds and Share Credit Timeline
If you did not get allotment, here’s the schedule you need to know:
| Activity | Date |
| Refund Initiation | July 18, 2025 |
| Credit of Shares to Demat | July 19, 2025 |
| Expected Listing Date | July 21, 2025 |
All refunds will be processed automatically to your linked bank accounts.
Should You Hold or Sell on Listing?
Reasons to Hold:
- Strong industry growth in biotech & CRAMS
- Consistent revenue growth & margins
- Long-term institutional confidence
- Robust export presence
- India’s booming healthcare & life sciences sector
Reasons Some Might Sell:
- Already priced-in premium through GMP
- Volatile post-listing behavior
- Profit booking temptation after 25% gain
Ideal Strategy: If you are a long-term investor, holding may provide better compounded returns. Short-term traders might want to consider selling if listing gains are above 25–30%.
Financial Snapshot
| Metric | FY 2023 |
| Revenue | ₹1,290 Cr |
| EBITDA Margin | 29.6% |
| Net Profit | ₹210 Cr |
| Return on Equity (RoE) | 18.2% |
| Debt-to-Equity Ratio | 0.45 |
| Order Book Growth (YoY) | 22% |
Strong earnings, clean balance sheet, and rising global demand for biotech services make Anthem a lucrative long-term bet.
Promoters and Shareholding
- Promoter: Dr. Suresh Ramu
- Pre-IPO Holding: 78.3%
- Post-IPO Promoter Holding: ~62% (estimated)
- Anchor Investors: SBI Mutual Fund, Axis MF, HDFC Life, etc.
The anchor book was subscribed before public bidding, bringing in ₹450 Cr — a positive signal for retail investors.
Market Opportunity: Indian CRAMS Industry
India’s contract research and manufacturing services (CRAMS) sector is projected to grow at a CAGR of 12–14% through 2030. With increased outsourcing from the US and EU pharma giants, India’s regulatory expertise and cost advantage make it a global hub.
Anthem’s investments in R&D, manufacturing automation, and cleanroom tech place it at the center of this growth wave.
Expert Analyst Views
- ICICI Direct: “Robust demand and diversified customer base support long-term growth.”
- Motilal Oswal: “Valuations appear fair considering industry tailwinds and operational margins.”
- Angel One: “GMP reflects positive sentiment. Listing pop is highly likely.”
Final Words
The Anthem Biosciences IPO has undoubtedly become one of 2025’s hottest public issues, driven by solid fundamentals, a booming sector, and strong investor demand. With allotment now complete and the listing day around the corner, investors are gearing up for action. Whether you’re a long-term biotech believer or a short-term opportunist, Anthem’s debut on the bourses will be one to watch closely.
Let me know if you want the same content converted into a PDF or need a social media post around it.
Frequently Asked Questions (FAQs)
Q1. When was Anthem Biosciences IPO allotment finalized?
Allotment was finalized on July 17, 2025.
Q2. How to check IPO allotment status?
Use KFintech’s portal or BSE/NSE IPO status pages with your PAN or application number.
Q3. What is the listing date?
Expected listing date is July 21, 2025 on NSE and BSE.
Q4. What is the GMP of Anthem Biosciences?
The grey market premium ranges between ₹138-154 per share.
Q5. What returns are expected on listing?
Analysts expect a 24-27% premium on listing based on current GMP.
Q6. What is the lot size for retail investors?
1 lot = 26 shares. Minimum investment was approx ₹14,820.
Q7. Who is the registrar of the IPO?
KFin Technologies Ltd.
Q8. What sector does Anthem Biosciences operate in?
Pharma & Biotech – specifically contract research and manufacturing (CRAMS).
Q9. Was the IPO oversubscribed?
Yes, it was subscribed 64 times overall.
Q10. Should I hold or sell the stock after allotment?
Long-term holders may benefit from compounding, but traders may book profits on listing if the price jumps 25-30%.